STOCK TITAN

Westfield Capital reports 0 shares of Bicycle Therapeutics (BCYC) on Schedule 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Bicycle Therapeutics plc received an amended Schedule 13G/A filing from Westfield Capital Management Company, L.P. reporting 0 shares beneficially owned of common stock, representing 0% as of 12/31/2025. The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, dated 03/03/2026.

Positive

  • None.

Negative

  • None.

Insights

Amendment confirms no beneficial ownership as of the reporting date.

The filing is an amended Schedule 13G/A from Westfield Capital Management Company, L.P. stating 0 shares and 0% ownership as of 12/31/2025. This is a routine ownership disclosure update rather than a transaction.

Timing and signature are shown: signed by Brandi McMahon on 03/03/2026. Subsequent filings would show any change in holdings.

Disclosure indicates no reportable stake, limiting immediate governance influence.

The schedule explicitly lists zero votes and zero dispositive power for Westfield across all categories, consistent with ownership of 5 percent or less disclosures. This filing does not alter board composition or shareholder voting dynamics.

Investors seeking changes in ownership should watch future amendments or Section 13 filings for updated share counts and percentages.






12/31/2025

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Westfield Capital Management Company, L.P.
Signature:Brandi McMahon
Name/Title:Vice President, Deputy Chief Compliance Officer
Date:03/03/2026

FAQ

What does Westfield Capital report in the BCYC Schedule 13G/A?

The filing reports 0 shares beneficially owned of Bicycle Therapeutics common stock, representing 0% of the class as of 12/31/2025. It is an amended disclosure signed on 03/03/2026.

Does the Schedule 13G/A indicate any voting or dispositive power for Westfield Capital?

No. The schedule lists 0 for sole and shared voting power and for sole and shared dispositive power. The filer reports no authority to vote or dispose of BCYC shares as of 12/31/2025.

Who signed the amended Schedule 13G/A for BCYC and when?

The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, with a signature date of 03/03/2026. The reporting person is Westfield Capital Management Company, L.P.

Is this Schedule 13G/A a transaction filing for BCYC?

No. This is an ownership disclosure amendment reporting a passive position of 0 shares. It does not report a purchase or sale transaction; it updates beneficial ownership information as of 12/31/2025.
Bicycle Therapeutics Limited

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Latest SEC Filings

BCYC Stock Data

397.48M
49.19M
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
CAMBRIDGE